Algernon Pharmaceuticals Inc.
Algernon Pharmaceuticals Inc.
- Market cap
- $1.09M
Your view on AGNPF
Overview
What the company does, where it operates, and who runs it.
About Algernon Pharmaceuticals Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Christopher J. Moreau
- Headquarters
- 700 West Pender Street, Vancouver, BC, CA
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Christopher J. Moreau
- Headquarters
- 700 West Pender Street, Vancouver, BC, CA
Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of nonalcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19 in Canada and Australia.
The company's lead candidate is NP-120, an N-methyl-d-aspartate (NMDA) receptor glutamate receptor antagonist, which targets NMDA-type subunit 2B (Glu2NB), as well as exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress.
It is also developing AP-188, a psychedelic compound that is part of the tryptamine family for the treatment of ischemic stroke in humans. Algernon Pharmaceuticals Inc. has an agreement with Charles River Laboratories for preclinical studies of AP-188 for the company's stroke clinical research program.
Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Algernon Pharmaceuticals Inc.. Starting points for Algernon Pharmaceuticals Inc.: EPS -$0.36, beta 1.25 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Algernon Pharmaceuticals Inc.. Algernon Pharmaceuticals Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Algernon Pharmaceuticals Inc.. Trailing twelve-month EPS for Algernon Pharmaceuticals Inc. stands at -$0.36. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Algernon Pharmaceuticals Inc.. Algernon Pharmaceuticals Inc. has reported as a listed company since 2016. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| NBTXNanobiotix S.A. | Healthcare | NASDAQ | $1.2B | ||
| NC6.AXNanollose Limited | Healthcare | ASX | — | ||
| NCELNewcelX Ltd. | Healthcare | NASDAQ | $1.1M | ||
| NCNANuCana plc | Healthcare | NASDAQ | $4.6M | ||
| NDTPNDT Pharmaceuticals Inc. | Healthcare | OTC | $143.2M | ||
| NERVMinerva Neurosciences, Inc. | Healthcare | NASDAQ | $99.7M | ||
| NEU.AXNeuren Pharmaceuticals Limited | Healthcare | ASX | — | ||
| NEUPNeuphoria Therapeutics Inc. | Healthcare | NASDAQ | $12.7M | ||
| NGNENeurogene Inc. | Healthcare | NASDAQ | $350.0M | ||
| NICXFNicox S.A. | Healthcare | OTC | $30.9M | ||
| NIKINiki BioSolutions, Inc. | Healthcare | NASDAQ | $127,856 | ||
| NKGNNKGen Biotech, Inc. Common Stock | Healthcare | OTC | $2.6M | ||
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Algernon Pharmaceuticals Inc.. Coverage tracks Algernon Pharmaceuticals Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Algernon Pharmaceuticals Inc.